Cell cycle checkpoint kinase (CHK)1 inhibition induces immune modulation in recurrent BRCA wild-type high-grade serous ovarian cancer (HGSOC) patients

被引：0
|
作者：
Lampert, Erika J. [1 ]
Lee, Min-Jung [1 ]
Trepel, Jane B. [1 ]
Yuno, Akira [1 ]
Cimino-Mathews, Ashley [2 ]
Lee, Joo-Sang [1 ]
Ruppin, Eytan [1 ]
Nair, Jayakumar [1 ]
Ekwede, Irene [1 ]
Lee, Jung-Min [1 ]
机构：
[1] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-5000
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5000
引用
收藏
页数：2
相关论文
共 50 条
  • [21] STAT1 associated immune checkpoint expression and immune cell localization represent adaptive immune resistance in high-grade serous ovarian cancer
    Li, Deyang
    Vidotto, Thiago
    Shakfa, Noor
    Afriyie-Asante, Afrakoma
    Peterson, Nichole
    de Ladurantaye, Manon
    Mes-Masson, Anne-Marie
    Francis, Julie-Ann
    Koti, Madhuri
    JOURNAL OF IMMUNOLOGY, 2021, 206
  • [22] Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
    Launonen, I-M
    Lyytikainen, N.
    Casado, J.
    Anttila, E. A.
    Szabo, A.
    Haltia, U-M
    Jacobson, C. A.
    Lin, J. R.
    Maliga, Z.
    Howitt, B. E.
    Strickland, K. C.
    Santagata, S.
    Elias, K.
    D'Andrea, A. D.
    Konstantinopoulos, P. A.
    Sorger, P. K.
    Farkkila, A.
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [23] Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer
    I.-M. Launonen
    N. Lyytikäinen
    J. Casado
    E. A. Anttila
    A. Szabó
    U.-M. Haltia
    C. A. Jacobson
    J. R. Lin
    Z. Maliga
    B. E. Howitt
    K. C. Strickland
    S. Santagata
    K. Elias
    A. D. D’Andrea
    P. A. Konstantinopoulos
    P. K. Sorger
    A. Färkkilä
    Nature Communications, 13
  • [24] URI1, BRCA1/BRCA2 and CCNE1 as potential drivers of a poor: Prognosis subset of High-grade Serous Ovarian Cancer (HGSOC)
    Aziz, D.
    Etemadmoghadam, D.
    Yeung, G. Au
    Muranyi, A.
    Gresshoff, I.
    Christie, M.
    Tubbs, A.
    Shanmugam, K.
    Boyden, D.
    Waring, P.
    VIRCHOWS ARCHIV, 2016, 469 : S20 - S21
  • [25] A phase II study of the cell cycle checkpoint kinases 1 and 2 inhibitor (LY2606368; Prexasertib monomesylate monohydrate) in sporadic high-grade serous ovarian cancer (HGSOC) and germline BRCA mutation-associated ovarian cancer (gBRCAm plus OvCa)
    Lee, J-M.
    Karzai, F. H.
    Zimmer, A.
    Annunziata, C. M.
    Lipkowitz, S.
    Parker, B.
    Houston, N.
    Ekwede, I.
    Kohn, E. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
    Kyung Jin Eoh
    Hye Min Kim
    Jung-Yun Lee
    Sunghoon Kim
    Sang Wun Kim
    Young Tae Kim
    Eun Ji Nam
    BMC Cancer, 20
  • [27] Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
    Eoh, Kyung Jin
    Kim, Hye Min
    Lee, Jung-Yun
    Kim, Sunghoon
    Kim, Sang Wun
    Kim, Young Tae
    Nam, Eun Ji
    BMC CANCER, 2020, 20 (01)
  • [28] Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.
    Launonen, Inga-Maria P.
    Lyytikainen, Nuppu
    Casado, Julia
    Anttila, Ella A.
    Jacobson, Connor A.
    Lin, Jia R.
    Maliga, Zoltan
    Santaga, Sandro
    Elias, Kevin M.
    D'Andrea, Alan D.
    Konstantinopoulos, Panagiotis A.
    Sorger, Peter K.
    Farkkila, Anniina
    CANCER RESEARCH, 2021, 81 (13)
  • [29] Comparison of Survival Outcomes According to BRCA1/2 Variant Type in High-grade Serous Ovarian Cancer
    Lee, Juhun
    Kim, Jong Mi
    Lee, Yoon Hee
    Chong, Gun Oh
    Lee, Nan Young
    Lee, In Hee
    Park, Ji Young
    Hong, Dae Gy
    IN VIVO, 2022, 36 (04): : 1903 - 1910
  • [30] The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition
    Parmar, Kalindi
    Kochupurakkal, Bose S.
    Lazaro, Jean-Bernard
    Wang, Zhigang C.
    Palakurthi, Sangeetha
    Kirschmeier, Paul T.
    Yang, Chunyu
    Sambel, Larissa A.
    Farkkila, Anniina
    Reznichenko, Elizaveta
    Reavis, Hunter D.
    Dunn, Connor E.
    Zou, Lee
    Do, Khanh T.
    Konstantinopoulos, Panagiotis A.
    Matulonis, Ursula A.
    Liu, Joyce F.
    D'Andrea, Alan D.
    Shapiro, Geoffrey I.
    CLINICAL CANCER RESEARCH, 2019, 25 (20) : 6127 - 6140
12345